Introduction
Seasonal influenza continues to be an unavoidable public health threat causing an estimated 250 000-500 000 deaths worldwide and 30 000-50 000 deaths in the United States annually. 1 Influenza outbreaks caused by different strains of types A and B viruses are usually the result of antigenic changes in the surface glycoproteins of the virus, enabling the new variants to escape immunity generated by vaccination or infection by previously circulating strains. In fact, significant antigenic drift is often associated with influenza epidemics, including those caused by A ⁄ Sydney ⁄ 05 ⁄ 97-like strains in 1997 and the A ⁄ Fujian ⁄ 411 ⁄ 02-like strains in 2003. 2, 3 While vaccination remains the most effective tool to fight against influenza epidemics, this continual antigenic drift requires vaccines to be reformulated on an annual basis. 2 Currently, most manufacturers use embryonated eggs to produce influenza vaccines. However, there are some disadvantages in using this vaccine substrate. For example, occasionally, a particular virus strain recommended for vaccine production, such as A ⁄ Fujian ⁄ 411 ⁄ 02 or some of influenza B viruses, 2, 4 does not replicate well in eggs resulting in vaccine shortage.
On June 11, 2009 , the World Health Organization raised the global alert level to Phase 6, the Pandemic phase, in response to the emergence and global spread of the novel H1N1 influenza A virus that appears to result from reassortment among human, avian, and swine viruses. Although the novel H1N1 virus belongs to the subtype prevalent for the most of the 20th century, only a fraction of the population (elderly) had some preexisting immunity, 5 suggesting an unpredictable nature of changes that may 6 The speed by which this virus spread and the potential devastation it may have caused make the capability for rapid development and manufacturing of a pandemic influenza vaccine in sufficient quantities a global priority. The development of novel substrates and approaches such as cell culture or recombinant protein-based vaccines is a promising step toward the rapid, large-scale production of both pandemic and seasonal vaccines.
During the past decade, plants have emerged as an economic and efficient large-scale production platform for vaccine antigens. 7, 8 More specifically, plant virus-based transient expression systems show further promise for producing high levels of target in a short period of time. 9, 10 We have previously described a novel transient expression system for the production of vaccine antigens in plants -a 'launch vector' system that combines the elements of plant RNA viral vectors and an Agrobacterium binary plasmid.
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This approach enables uniform, high levels of target protein expression and rapid scale-up of production. Vaccine antigens produced in this system have been shown to elicit protective immune responses in animal models. 12, 13 Here, we demonstrate the potential of our transient plant expression system to produce hemagglutinin (HA) proteins from the influenza strains comprising the 2008-2009 seasonal vaccine (A ⁄ Brisbane ⁄ 59 ⁄ 07, A ⁄ Brisbane ⁄ 10 ⁄ 07, and B ⁄ Florida ⁄ 4 ⁄ 06) and from the novel H1N1 influenza A strain (A ⁄ California ⁄ 04 ⁄ 09), and evaluate immunogenicity of these plant-produced proteins in mice.
Materials and methods

Ethics statement
All animal protocols were approved by the University of Delaware Institutional Animal Care and Use Committee under Animal Use Protocol Number 1173.
Cloning and expression of HA antigens in plants
The HA sequences, encompassing amino acids 18-529 of the A ⁄ Brisbane ⁄ 59 ⁄ 07, 17-529 of the A ⁄ Brisbane ⁄ 10 ⁄ 07, 15-547 of the B ⁄ Florida ⁄ 4 ⁄ 06 or 17-530 of the A ⁄ California ⁄ 04 ⁄ 09 strains of influenza viruses (accession number ACA28844, ABW23353, ACA33493 or ACP41105, respectively), were optimized for expression in plants and synthesized by GENE-ART AG (Regensburg, Germany) as described previously. 12 Each optimized HA sequence was then inserted into the launch vector pGRD4 as described elsewhere. 12 The pGRD4 vector carrying the target sequence was introduced into the Agrobacterium tumefaciens strain GV3101 along with pSoup that provides replication functions in trans. 14 The resulting bacteria were then grown in a minimal medium overnight at 28°C. The optical density of the Agrobacterium culture was determined and adjusted to approximately 0AE5. The Agrobacterium culture was introduced by hand infiltration into the aerial parts of 6-week-old soil-grown Nicotiana benthamiana plants as described previously. 15 The expression levels of a target protein in plant leaves and its solubility were monitored daily from 5 to 7 days post-infiltration (DPI) by Western blot analysis using an anti-hexa-histidine (6xHis) tag mouse monoclonal antibody (mAb) (Roche Applied Science, Indianapolis, IN, USA). The image was taken using the GeneSnap software on a GeneGnome and quantified using the Gene Tools software (Syngene Bioimaging, Frederick, MD, USA). The day of the maximum expression was determined for production purposes. Scale-up infiltration of hydroponic trays of N. benthamiana was then performed by vacuum as described previously, 15 and the tissue was harvested at the time of peak expression for purification. A schematic diagram of the target protein production in N. benthamiana using the launch vector system is shown in Figure 1 .
Purification and in vitro characterization of plant-produced HA antigens
Aerial tissues of N. benthamiana expressing each HA antigen were harvested at 7 DPI and then frozen at )80°C until the day of purification. The frozen tissues were mechanically homogenized and incubated with 0AE5% Triton X-100. The crude extracts were then clarified by centrifugation (78 000 g for 30 min) and microfiltration. After clarification, the extracts were initially purified using immobilized metal affinity chromatography (Ni-sepharose; GE Healthcare, Piscataway, NJ, USA) with Ni buffer A (50 mM sodium phosphate, 500 mM NaCl, 20 mM imidazole, pH 7AE5) as a binding and washing buffer and 60% Ni buffer B (Ni buffer A with 500 mM imidazole) as an elution buffer. Further purification was carried out by anionexchange chromatography (Capto Q; GE Healthcare) with Q buffer A (10-50 mM sodium phosphate, pH 5AE8) as a Plant-based production of influenza vaccines ª 2011 Blackwell Publishing Ltd loading buffer on a Bio-Rad Duo Flow system (Bio-Rad Laboratories, Hercules, CA, USA) using the Biologics software. Purified antigens were then dialyzed against phosphate-buffered saline (PBS) and quantified by absorbance of UV at 280 nm. Purified HA antigens were separated on 10% SDS-PAGE followed by staining with Coomassie blue (Pierce, Rochford, IL, USA) for analysis of their molecular weight and purity. The purified HA antigens from A ⁄ Brisbane ⁄ 59 ⁄ 07, A ⁄ Brisbane ⁄ 10 ⁄ 07, B ⁄ Florida ⁄ 4 ⁄ 06, and A ⁄ California ⁄ 04 ⁄ 09 were designated as HAB1(H1), HAB1(H3), HAF1(B), and HAC1, respectively.
Immunogenicity of plant-produced HA antigens in mice
Groups of 6-week-old Balb ⁄ c mice, 6 mice per group, were immunized with HAB1(H1), HAB1(H3), or HAF1(B) subcutaneously (s.c.) at 2-week intervals at days 0, 14, and 28. Three different antigen doses were tested: 60, 30, and 15 lg in 50 ll of PBS. All immunizations included 10 lg of Quil A as an adjuvant (Accurate Chemicals, Westbury, NY, USA). Serum samples were collected prior to each immunization and 2 weeks after the third dose. Animals in control groups received PBS with 10 lg of Quil A. In another study, groups of Balb ⁄ c mice were immunized with HAC1 twice at a 3-week interval (days 0 and 21) either s.c. with doses of 30, 15, or 5 lg with 10 lg of Quil A or intramuscularly (i.m.) with a dose of 30 lg absorbed to Alhydrogel (1:20 w ⁄ w) (Accurate Chemicals, Westbury, NY, USA). As in the first study, animals in control groups received PBS with 10 lg of Quil A. Serum samples were collected prior to each immunization, as well as 10 and 21 days after the second immunization. Serum IgG and hemagglutination inhibition (HI) antibody titers were determined as described later.
Assessment of serum antibody titers
Serum IgG titers were measured using enzyme-linked immunosorbent assay (ELISA) using 96-well MaxiSorp plates (NUNC, Rochester, NY, USA) coated with inactivated A ⁄ Brisbane 59 ⁄ 07 (NIBSC 07 ⁄ 346), A ⁄ Brisbane ⁄ 10 ⁄ 07 (TGA 2007 ⁄ 79B, Australia), or B ⁄ Florida ⁄ 4 ⁄ 06 (NIBSC 08 ⁄ 140) virus as described previously. 12 For the IgG-specific ELISA of serum samples from HAC1-immunized mice, A ⁄ California ⁄ 07 ⁄ 09 · 179A (CDC # 2009713114, Georgia AT) was grown in embryonated eggs and inactivated with b-propiolactone (Sigma Aldrich, St Louis, MO, USA). ELISA plates were coated with inactivated A ⁄ California ⁄ 07 ⁄ 09 virus at 320 HA U ⁄ ml in PBS. Samples of sera were tested in a series of fourfold dilutions, and antigen-specific antibodies were detected using a horseradish peroxidase-conjugated goat anti-mouse IgG antibody (Jackson Immunoresearch Laboratories Inc., West Grove, PA, USA).
For the HI assay, serum samples from immunized animals were first treated with a receptor-destroying enzyme (RDE; Denka Seiken Co. Ltd., Tokyo, Japan). The HI assay was carried out using 0AE75% turkey erythrocytes as described Figure 2 . Expression and solubility profiles of hemagglutinin antigens produced in plants. Leaf tissue samples were collected at 7 DPI and homogenized in the extraction buffer without (total soluble protein: lane 1) or with 0AE5% Triton X-100 (total soluble protein with the detergent: lane 2), and with 1· gel loading buffer for total protein (lane 3). All samples were subjected to SDS-PAGE, and Western blot analysis was carried out using an anti-6xHis mouse mAb. 
Results and Discussion
Production and characterization of plant-produced HA antigens , each HA molecule was produced in agroinfiltrated N. benthamiana plants using our launch vector system. Optimum levels of expression were observed at 7 DPI for all four HA antigens (data not shown). The total target protein levels were determined to range from 400-1300 mg ⁄ kg of fresh leaf tissue. As shown in Figure 2 , HAB1(H1) and HAB1(H3) required the presence of Triton X-100 (0AE5%) for solubility, whereas HAF1(B) and HAC1 were soluble in the absence of the detergent.
All four HA antigens were purified from N. benthamiana plants using His-tag-based affinity chromatography. 10 As shown by SDS-PAGE analysis, the purity of the final preparations of the plant-produced HA antigens was >85% (Figure 3 ).
Immunogenicity of plant-produced HA antigens in mice
The immunogenicity of the plant-produced HA antigens was individually evaluated in mice. Following immunization, samples of sera were collected, and both HA-specific IgGs and HI antibody titers were measured. All animals immunized with HAB1(H1), HAB1(H3), or HAF1(B) showed serum HA-specific IgG responses that increased after the antigen boosts (Figure 4) . Of the animals immunized with a 60, 30, or 15 lg dose of HAB1(H1), 33AE3%, 16AE7%, and 33AE3% of mice, respectively, had detectable serum HI antibodies after the first antigen boost, and these titers increased after the second antigen boost (Table 1 and Figure 5 , left panel). After the second antigen boost, the proportions of seropositive animals in the groups that received a 15 or 30 lg dose of HAB1(H1) reached 100% (Table 1) . Similarly, HI titers and seropositive rates increased after the second antigen boost among animals immunized with HAB1(H3) or HAF1(B) ( Table 1 and Evaluation of HAC1-specific immune responses in mice immunized s.c. with HAC1 and Quil A adjuvant demonstrated that 100% of animals receiving a 30 lg dose and 83% of animals receiving a 15 or 5 lg dose of the antigen had serum IgG against A ⁄ California ⁄ 07 ⁄ 09 after the primary immunization (data not shown), and the titers significantly increased after the antigen boost ( Figure 6 ). Similar results were observed in mice immunized with a 30 lg Figure 5 . Titers of hemagglutination inhibition (HI) antibodies against seasonal influenza strains. Mice were immunized with HAB1(H1), HAB1(H3), or HAF1(B) three times, at days 0, 14, and 28, and serum samples were collected prior to each immunization and 2 weeks after the third dose (study day 42). Anti-A ⁄ Brisbane ⁄ 59 ⁄ 07, A ⁄ Brisbane ⁄ 10 ⁄ 07, and B ⁄ Florida ⁄ 4 ⁄ 06 HI antibody titers were expressed as the reciprocal of the highest dilution of serum that inhibits hemagglutination of eight hemagglutinin units of each virus. Samples without detectable HI antibody titers were assigned a titer of 10. Data shown are the mean titers (log 2 ) from each group of immunized mice ± SE. Figure 6 . Titers of hemagglutinin-specific IgG antibodies in mice immunized with HAC1. Mice were immunized with HAC1 twice, at days 0 and 21, and serum samples were collected prior to each immunization, as well as 10 and 21 days after the second dose (study days 31 and 42, respectively). The HAC1 antigen was administered to mice either in the presence of Quil A (s.c.) or adsorbed to Alhydrogel (i.m.). Anti-A ⁄ California ⁄ 07 ⁄ 09 IgG antibody titers were expressed as the mean serum IgG titers ± SE.
dose of HAC1 absorbed to Alhydrogel and administered i.m. (Figure 6 ).
Serum HI antibody responses in mice immunized s.c. with HAC1 and Quil A were evaluated using A ⁄ California ⁄ 07 ⁄ 09 or A ⁄ Texas ⁄ 5 ⁄ 09, two novel H1N1 influenza A virus strains. Ten days after the antigen boost, all animals had very high serum HI antibody titers against A ⁄ California ⁄ 07 ⁄ 09 (Figure 7 , left panel). These titers slightly increased by 21 days after the antigen boost, reaching geometric mean titers [±standard errors (SE)] of 1:1810AE2 ± 347AE3, 1:1810AE2 ± 373AE3, or 1:806AE3 ± 429AE5 at a 30, 15, or 5 lg antigen dose, respectively (Table 2 and Figure 7 , left panel). Animals that were immunized i.m. with a 30 lg ⁄ dose of HAC1 with Alhydrogel, which is the only adjuvant currently approved in the USA for human use, also showed substantial serum HI antibody production at 10 days after the antigen boost ( Figure 7, left panel) . Although the mean titer was lower compared to the mice immunized with HAC1 and Quil A, it was ‡1:40 in all animals at 10 days after the antigen boost and reached the level of 1:718AE4 ± 350AE5 at 21 days after the antigen boost (Table 2) . Furthermore, all animals immunized with HAC1 Figure 7 . Titers of hemagglutination inhibition (HI) antibodies against the novel H1N1 influenza A strains. Mice were immunized with HAC1 twice, at days 0 and 21, and serum samples were collected prior to each immunization, as well as 10 and 21 days after the second dose (study days 31 and 42, respectively). The HAC1 antigen was administered to mice either in the presence of Quil A (s.c.) or adsorbed to Alhydrogel (i.m.). Anti-A ⁄ California ⁄ 07 ⁄ 09 and A ⁄ Texas ⁄ 5 ⁄ 09 HI antibody titers were expressed as the reciprocal of the highest dilution of serum that inhibits hemagglutination of eight hemagglutinin units of each virus. Samples without detectable HI titers were assigned a titer of 10. Data shown are the mean titers (log 2 ) from each group of immunized mice ± SE. In summary, we engineered and produced recombinant HA antigens from seasonal influenza vaccine strains, A ⁄ Brisbane ⁄ 59 ⁄ 07, A ⁄ Brisbane ⁄ 10 ⁄ 07, and B ⁄ Florida ⁄ 4 ⁄ 06, and from the novel H1N1 influenza A strain, A ⁄ California ⁄ 04 ⁄ 09, in N. benthamiana plants using our launch vector system. As shown in Figure 1 , these recombinant HAs were available as final vaccine antigens within 2 months of obtaining the amino acid sequences. Immunization of mice with these plant-produced HA antigens induced serum IgG and HI antibody responses at the levels considered protective, showing the feasibility of our launch vector system for the rapid production of immunogenic vaccine antigens at a medium scale (1 kg of fresh biomass) in response to pandemic disease outbreaks, suggesting a potential for scaleup. Recently, we have produced HAC1 in N. benthamiana plants at the large scale (50 kg of plant biomass) under cGMP conditions, purified it to the average yield of 90 mg ⁄ kg and demonstrated its safety and immunogenicity in preclinical animal models. 16 Currently, safety and immunogenicity of this plant-produced H1N1 influenza vaccine candidate are being evaluated in a Phase 1 clinical trial. 17 
